Search research articles
Contact Us
Filters
Showing results (61-70 of 84) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2016
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
K Koch, E Hoster, M Ziepert, et al.
Leukemia
|
July 17, 2014
Genomic and epigenomic co-evolution in follicular lymphomas
M Loeffler, M Kreuz, A Haake, et al.
Leukemia
|
August 20, 2016
Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma
K D Wurster, F Hummel, J Richter, et al.
Journal of Clinical Pathology
|
September 17, 2008
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)
D de Jong, W Xie, A Rosenwald, et al.
Leukemia
|
August 6, 2011
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma
M Deckert, A Engert, W Brück, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2021
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status
G A Croci, R K H Au-Yeung, S Reinke, et al.
Leukemia
|
September 27, 2008
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
C Buske, E Hoster, M Dreyling, et al.
Leukemia
|
March 30, 2025
Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials
P J Bröckelmann, H Müller, M Fuchs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials
P J Bröckelmann, H Müller, M Fuchs, et al.
Der Pathologe
|
November 27, 2012
[Round robin test for detection of genomic aberrations in non-Hodgkin lymphoma by in situ hybridization]
T F E Barth, L Floßbach, H-W Bernd, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 84) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2016
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
K Koch, E Hoster, M Ziepert, et al.
Leukemia
|
July 17, 2014
Genomic and epigenomic co-evolution in follicular lymphomas
M Loeffler, M Kreuz, A Haake, et al.
Leukemia
|
August 20, 2016
Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma
K D Wurster, F Hummel, J Richter, et al.
Journal of Clinical Pathology
|
September 17, 2008
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)
D de Jong, W Xie, A Rosenwald, et al.
Leukemia
|
August 6, 2011
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma
M Deckert, A Engert, W Brück, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2021
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status
G A Croci, R K H Au-Yeung, S Reinke, et al.
Leukemia
|
September 27, 2008
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
C Buske, E Hoster, M Dreyling, et al.
Leukemia
|
March 30, 2025
Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials
P J Bröckelmann, H Müller, M Fuchs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials
P J Bröckelmann, H Müller, M Fuchs, et al.
Der Pathologe
|
November 27, 2012
[Round robin test for detection of genomic aberrations in non-Hodgkin lymphoma by in situ hybridization]
T F E Barth, L Floßbach, H-W Bernd, et al.
Page
of 9